摘要
脑是非小细胞肺癌(non-small cell lung cancer, NSCLC)最常见的远处转移部位,脑转移也是晚期肺癌致残致死的主要原因。近年来,小分子酪氨酸激酶抑制剂的应用和疗效奠定了驱动基因突变阳性的NSCLC脑转移的治疗基础。随着程序性死亡受体1(programmed cell death protein 1, PD-1)/程序性死亡受体配体1(programmed cell death protein ligand 1, PD-L1)抑制剂及相应联合疗法的不断发展,免疫治疗已成为驱动基因突变泛阴性的NSCLC脑转移患者的重要选择,相关生物标志物的价值也日益凸显。由于NSCLC脑转移肿瘤及其微环境的免疫病理特征具有一定的特殊性,本文旨在回顾相关研究进展,并为免疫治疗联合策略的探索与新型免疫疗法的开发提供参考。
Brain is the most frequent site for distant metastases of non-small cell lung cancer(NSCLC). Brain metastasis(BM) is also the leading cause of disabilities and death in advanced NSCLC. In recent years, the application and effectiveness of small-molecule tyrosine kinase inhibitors has formed the basis for the treatment of NSCLC brain metastases with driver gene mutations. With the development of programmed cell death protein 1(PD-1)/programmed cell death protein ligand 1(PD-L1) inhibitors and relevant combination therapies, immunotherapy has become an important choice for non-classic oncogene addicted NSCLC BM patients. Also, the roles of relevant biomarkers are increasingly standing out. By reason of the particular immunopathological features of NSCLC brain metastases and its microenvironment, the aim of this review is to summarize relevant research progresses and provide more references for combination strategies of different therapeutic methods as well as the development of novel immunotherapies.
作者
兰青
纪春霞
姚瑜
Qing LAN;Chunxia JI;Yu YAO(Department of Neurosurgery,Huashan Hospital,Fudan University,Shanghai 200040,China)
出处
《中国肺癌杂志》
CAS
CSCD
北大核心
2019年第8期512-519,共8页
Chinese Journal of Lung Cancer
基金
国家自然科学基金面上项目（No.81572478）资助~~
关键词
肺肿瘤
脑转移
免疫治疗
肿瘤微环境
Lung neoplasms
Brain metastases
Immunotherapy
Tumor microenvironment
